Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT200 + docetaxel
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SCT200 + docetaxel is a combination therapy consisting of SCT200, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and docetaxel, a semi-synthetic member of the taxoid class that promotes and stabilizes microtubule assembly, thereby inhibiting cell division. SCT200 inhibits EGFR-mediated signaling pathways involved in tumor growth and survival, while docetaxel disrupts microtubular networks in cells, preventing mitosis. This combination is being investigated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have previously failed platinum-based chemotherapy and programmed cell death protein 1 (PD-1) inhibitor therapy[1][2][3].
- Brand names
- ACT DOCEtaxelTaro-DOCEtaxel
- Other names
- SCT200 + docetaxel
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SCT200 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT200 + docetaxel.